Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Collegium Pharmaceutical Q3 2026 Results: Net Income $21.8M, Down 30.9% YoY

Collegium Pharmaceutical reported net income of $21.8 million for the third quarter of 2026, a decrease from $31.5 million in the prior year period, despite a slight increase in product revenues to $216.3 million. The company completed the acquisition of Azstarys during the nine-month period, contributing to a significant increase in total assets to $2.1 billion and a rise in operating expenses due to higher selling, general, and administrative costs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue216.3209.4
Gross profit125.4129.2
Profit before tax7.943.4
Net income21.831.5
EPS (diluted, $ a share)$0.60$0.84

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-30.9%
Revenue, year on year+3.3%
Gross margin58.0%
Operating margin13.3%
Source

10-Q filed with the SEC, NASDAQ: COLL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Collegium Pharmaceutical, Inc: key numbers

Share price
$25.43Close, Nov 16
Market cap
$790M
Shares outstanding
31.08MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Collegium Pharmaceutical, Inc

All →
7:33 AM ET 8-K
Financial Results

Collegium Pharmaceutical Financial Results

Collegium Pharmaceutical reported record Q3 2026 net revenue of $216.3 million, driven by strong performance in its ADHD portfolio, including record JORNAY PM sales and the first full quarter of AZSTARYS revenue. The company reaffirmed its full-year 2026 financial guidance and expects to complete its $50 million accelerated share repurchase program by year-end.

Term
Q3 2026

“We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year.”

Vikram Karnani, President and Chief Executive Officer

“We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue.”

Colleen Tupper, Chief Financial Officer
4:05 PM ET 8-K
Court & Legal Update

Collegium Pharmaceutical Court & Legal Update

Collegium Pharmaceutical entered into a settlement agreement with Grünenthal GmbH to resolve patent infringement litigation related to Nucynta ER. As part of the settlement, Collegium will pay $17 million to terminate a 2015 license agreement and discharge all future royalty obligations. Additionally, Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the pending lawsuit.

Counterparty
Grünenthal GmbH

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.